Presentation,
22nd annual San Antonio Breast Cancer Symposium
(Source:
Breast Cancer Update for Surgeons, Program 1 2000)
Play
Audio Below:
In
the days when we only had palpable breast lesions, atypical hyperplasia
was uncommon. It accounted for only four percent of the 10,000 cases
in the landmark study of Dr. Paige. But if you look in studies of
mammographic screening, atypia is much more common. It accounts
for anywhere from eight percent to about 17 percent of lesions picked
up by screening mammography, depending on your patient population.
We know that atypical hyperplasia increases the risk of breast cancer
development, and atypical hyperplasia in the absence of a family
history of breast cancer was associated with a relative risk of
breast cancer development that was four to five times that of the
index population with non-proliferative lesions. And, if you have
the combination of atypical hyperplasia and a first-degree relative
with breast cancer, that risk goes up to nine.
Chemoprevention
of breast cancer [Review]. Brown, P. H. and Lippman, S. M. (Reprint available from: Lippman
SM Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent 1515
Holcombe Blvd,Box 236 Houston, TX 77030 USA). Breast Cancer Research
& Treatment. 62(1):1-17, 2000 Jul.
Vitamin
A analogue for breast cancer prevention: a grade of F or incomplete?
Response Piantadosi, S. (Reprint available from: Piantadosi S Johns Hopkins
Univ, Sch Med, Johns Hopkins Oncol Ctr 550 N Broadway,Suite 1103
Baltimore, MD 21205 USA).. Journal of the National Cancer Institute.
92(3):274-275, 2000 Feb 2. No abstract
Tamoxifen
for the prevention of breast cancer in the high-risk woman.
Morrow, M. and Jordan, V. C. (Reprint available from: Morrow M 676
N St Clair St,13th Floor, Room 13-104 Chicago, IL 60611 USA).. Annals
of Surgical Oncology. 7(1):67-71, 2000 Jan-Feb. No abstract
